aluxum Shares of Perspective Therapeutics ( NYSE: CATX ) traded higher on Wednesday after Truist launched its coverage with a Buy recommendation and a $21 per share target, arguing that its pipeline focused on radiopharmaceuticals looked underappreciated. Noting that CATX implies approximately $500M in peak.
Back to Health Page
